Laddar...
Towards personalized therapy for patients with glioblastoma
Combined therapy with temozolomide and radiotherapy is a standard treatment and improves the survival for patients with newly diagnosed glioblastoma. However, the prognosis remains poor, with a median survival time of 12–15 months. Currently, several clinical trials of dose-dense temozolomide regime...
Sparad:
| I publikationen: | Expert Rev Anticancer Ther |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2011
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4297206/ https://ncbi.nlm.nih.gov/pubmed/22117160 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/era.11.103 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|